

85



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/054,647	01/22/2002	Robert Lawton	00-1278-C	9151

20306 7590 01/28/2005

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 S. WACKER DRIVE  
32ND FLOOR  
CHICAGO, IL 60606

EXAMINER

FORD, VANESSA L

ART UNIT PAPER NUMBER

1645

DATE MAILED: 01/28/2005

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES PATENT AND TRADEMARK OFFICE

---

Commissioner for Patents  
United States Patent and Trademark Office  
P.O. Box 1450  
Alexandria, VA 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

**MAILED**

**JAN 28 2005**

**GROUP 1600**

**BEFORE THE BOARD OF PATENT APPEALS  
AND INTERFERENCES**

Application Number: 10/054,647  
Filing Date: January 22, 2002  
Appellant(s): LAWTON ET AL.

---

Robert Lawton, et al.  
For Appellant

**EXAMINER'S ANSWER**

This is in response to the appeal brief filed October 25, 2004.

**(1) *Real Party in Interest***

A statement identifying the real party in interest is contained in the brief.

**(2) *Related Appeals and Interferences***

A statement identifying the related appeals and interferences which will directly affect or be directly affected by or have a bearing on the decision in the pending appeal is contained in the brief.

**(3) *Status of Claims***

The statement of the status of the claims contained in the brief is correct.

**(4) *Claims on Appeal***

The Appeal involves claims 1-13.

**(5) *Status of Amendments After Final***

Appellant's statement that no amendments were presented after final is correct.

**(6) *Reservation of Right to Supplement Appeal Brief***

Appellant is incorrect in their statement that an Advisory Action has not been issued in this application. An Advisory Action was mailed November 10, 2004.

**(7) Summary of Invention**

The summary of invention contained in the brief is correct.

**(8) Issues**

The appellant's statement of the issues in the brief is substantially correct. The changes are as follows:

Claims 1-13 are unpatentable under 35 U.S.C. 112, first paragraph  
(written description).

Claims 1-13 are unpatentable under 35 U.S.C. 112, first paragraph  
(enablement).

Claims 1-13 are unpatentable under 35 U.S.C. 102(a).

Claims 1-9 are unpatentable under 35 U.S.C. 112, second paragraph.

**(9) Claims Appealed**

The copy of the appealed claims contained in the Appendix to the brief is correct.

**(10) Prior Art of Record**

WO 99/13720, 03/1999, Rikihisa et al.

**(11) Grounds of Rejection**

The following ground(s) of rejection are applicable to the appealed claims:

- I. Claims 1-13 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention. *This is a written description rejection.*

The specification broadly describes as a part of the invention a composition and an article of manufacture comprising the isolated polypeptide of SEQ ID No: 2 and variants thereof. The specification states that "variants in which amino acids of the polypeptides of the invention are substituted, deleted or added in any combination are contemplated by the invention". The specification also states "that naturally occurring variants and non-naturally occurring variants are included in the invention and may be produced by mutagenesis techniques or by direct synthesis" (page 7). Appellant has broadly described the invention as embracing any substitution, insertion or deletion change of amino acids throughout the length of the polypeptide sequence. Variants of SEQ ID No:2 correspond to sequences from other species, mutated sequences, allelic variants, spliced variants, sequences that have a variant degree of identity (similarity, homology), and so forth. None of these sequences meet the written description provision of 35 U.S.C. 112, first, paragraph. The specification provides insufficient written description to support the genus encompassed by the claim. Vas-Cath Inc. v. Mahurkar, 19 USPQ2d 1111, makes clear that "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in

Art Unit: 1645

possession of the invention. The invention is, for purposes of the 'written description' inquiry, *whatever is now claimed*." (See page 1117.) The specification does not "clearly allow persons of ordinary skill in the art to recognize that [he or she] invented what is claimed." (See Vas-Cath at page 1116.)

With the exception of SEQ ID NO:2, the skilled artisan cannot envision the detailed chemical structure of the encompassed polypeptide regardless of the complexity or simplicity of the method of isolation. Adequate written description requires more than a mere statement that it is part of the invention and reference to a potential method for isolating it. See Fiers v. Revel, 25 USPQ2d 1601, 1606 (CAFC 1993) and Amgen Inc. V. Chugai Pharmaceutical Co. Ltd., 18 USPQ2d 1016. In Fiddes v. Baird, 30 USPQ2d 1481, 1483, claims directed to mammalian FGF's were found unpatentable due to lack of written description for the broad class. The specification provided only the bovine sequence.

Therefore, only SEQ ID NO: 2 but not the full breadth of the claim (or none of the sequences encompassed by the claim) meets the written description provision of 35 USC 112, first paragraph. The species specifically disclosed are not representative of the genus because the genus is highly variant. Appellant is reminded that Vas-Cath makes clear that the written description provision of 35 USC 112 is severable from its enablement provision. (See page 1115.)

Art Unit: 1645

II. Claims 1-13 rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for a composition and an article of manufacture that comprise SEQ ID No:2, does not reasonably provide enablement for a composition or an article of manufacture that comprise variants of SEQ ID. NO:2. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention commensurate in scope with these claims.

Claims 1-13 are directed to compositions of matter and articles of manufacture comprising an isolated polypeptide consisting essentially of SEQ ID NO: 2 or phenotypically silent variants thereof.

The specification is enabling only for the polypeptides of SEQ ID NO:2. The specification states that "variants in which amino acids of the polypeptides of the invention are substituted, deleted or added in any combination are contemplated by the invention". The specification also states "that naturally occurring variants and non-naturally occurring variants are included in the invention and may be produced by mutagenesis techniques or by direct synthesis" (page 7). The specification teaches that there are many tolerable and conservative amino acid substitutions which can be made that are not critical to protein function (pages 7-9). There is no guidance provided as to which amino acids can be added, deleted or substituted and the polypeptide would retain its biological function. The scope of the claims is not commensurate with the enablement provided by the disclosure with regard to the extremely large number of polypeptides broadly encompassed by the claims and the claims broadly encompass a

significant number of inoperative species. Since the amino acid sequence of the polypeptide determines its structural and functional properties, predictability of which changes can be tolerated in a polypeptide's amino acid sequence and still retain similar activity requires a knowledge with regard to which amino acids in the polypeptide's sequence, if any, are tolerant of modification and which are conserved (i.e. expected intolerant to modification) and detailed knowledge of the ways in which the polypeptide's structure relates to function. However, the problem of the prediction of polypeptide structure from mere sequence data of a single polypeptide and in turn utilizing predicted structural determinations to ascertain functional aspects of the polypeptide and finally what changes can be tolerated with respect thereto is extremely complex and outside of the realm of routine experimentation.

While recombinant and mutagenesis techniques are known, it is not routine in the art to screen multiple substitutions or multiple modifications of other types and the positions within the polypeptide's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity are limited in any polypeptide and the result of such modifications is unpredictable based on the instant disclosure. One skilled in the art would not expect any tolerance to modifications, e.g., multiple substitutions. The sequence of some polypeptides is highly conserved and one skilled in the art would not expect tolerance to any amino acid modification in such polypeptides.

Factors to be considered in determining whether undue experimentation is required, are set forth in In re Wands 8 USPQ2d 1400. They include (1) the quantity of



Art Unit: 1645

experimentation necessary, (2) the amount of direction or guidance presented, (3) the presence or absence of working examples, (4) the nature of the invention, (5) the state of the prior art, (6) the relative skill of those in the art, (7) the predictability or unpredictability of the art and (8) the breadth of the claims.

Applying the above test to the facts of record, it is determined that 1) no declaration under 37 C.F.R. 1.132 or other relevant evidence has been made of record establishing the amount of experimentation necessary, 2) insufficient direction or guidance is presented in the specification with respect to selecting other antigens having claimed functional features, 3) the relative skill of those in the art is commonly recognized as quite high (post-doctoral level). One of skill in the art would require guidance, in order to make or use polypeptides that are variants of SEQ ID NO: 2 in a manner reasonable in correlation with the scope of the claims. Without proper guidance, the experimentation to is undue.

III. Claims 1-13 are rejected under 35 U.S.C. 102(a) as anticipated by Rikihisia et al (WO 99/13720, 03/1999).

Claims 1-13 are drawn to a compositions of matter and articles of manufacture comprising an isolated consisting essentially of SEQ ID NO:2 or a phenotypically silent substitution variants thereof that specifically bind to an anti-*Ehrlichia* antibody.

Rikihisia et al teach immunogenic compositions comprising the isolated polypeptide of SEQ ID NO:2 and pharmaceutically acceptable adjuvants (page 12).

Rikihisia et al teach an antigen (i.e. isolated polypeptide) used in a Western immunoblot

Art Unit: 1645

analysis and a dot blot analysis to detect the presence of antibody to *E. canis* ( page 17). The polypeptide of SEQ ID No: 2 is disclosed in Figure 19B. It is well known in the art to include packing material that comprises a label to indicate the intended use of the article of manufacture. The composition of matter and article of manufacture of Rikihisa, et al appears to be the same as the claimed invention.

Since the Office does not have the facilities for examining and comparing applicant's composition and article of manufacture with the composition and article of manufacture of the prior art, the burden is on the applicant to show a novel or unobvious difference between the claimed product and the product of the prior art (i.e., that the composition and article of manufacture of the prior art does not possess the same material structural and functional characteristics of the claimed composition and article of manufacture). See In re Best, 562 F.2d 1252, 195 USPQ 430 (CCPA 1977) and In re Fitzgerald et al., 205 USPQ 594.

Art Unit: 1645

IV. Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph.

Claims 1-9 are drawn to a composition of matter comprising an isolated consisting essentially of SEQ ID NO:2 or a phenotypically silent substitution variants thereof that specifically bind to an anti-*Ehrlichia* antibody.

Claims 1-9 are indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Claims 1-9 are indefinite because the claims recite "phenotypically silent substitutions variants". It is unclear as to what the Applicant is referring?

**(12) Response to Arguments**

*Response to Arguments Traversing the Rejection of claims 1-13 under 35 U.S.C.112, first paragraph (written description).*

Appellant urges that written description requires that one skilled in the art must recognize that the Appellant was in possession of the claimed genus, that is, variants of SEQ ID NO:2. Appellant refers to the Guidelines for Examination of Patent Applications under 35 U.S.C. 112, 66 Fed. Reg. 1099, 1106 (2001). Appellant urges that the description of a representative number of species does not require the description to be such specificity that it would provide individual support for each species that the genus embraces. Appellant urges that one species can adequately support a genus and that distinguishing characteristics of a claimed genus include A) partial structure, B) physical and/or chemical properties, C) functional characteristics, D) known or disclosed correlation between structure and function, E) method of making and F) combinations of

Art Unit: 1645

A-E. Appellant urges that the partial structure of the claimed variants are known, ( i.e. sequences having at least 85 % identity to SEQ ID NO:2 and therefore the variants have about 17 amino acids in common with the 20 amino acid long sequence as set forth in SEQ ID NO:2), that the specification teaches that amino acid substitution variants of the invention can be made and provides detailed guidance on how to construct variants of SEQ ID NO:2. Appellant asserts that Table 1 demonstrates that positions 3, 8, and 13 of SEQ ID NO:2 are highly conserved across the seven sequences and positions 1,4, 5, 6, 7, 9, 10, 11, 12 and 15 are partially conserved across the 7 sequences that is only 2 different amino acids appear in these positions. Appellant asserts that only K or N appear as amino acids in position 1 across the seven sequences and one of skill in the art would recognize that variants should likely retain the amino acids at positions 3, 8 and 13 and that one of two amino acids should likely be present at positions 1, 4, 5, 6, 7, 9, 10, 11, 12 and 15. Appellant urges that one of skill in the art would recognize that position 2, 14 and 16-20 could tolerate a greater range of amino acid substitutions and therefore the specification provides guidance for the claimed variants. Appellant urges that physical properties and functional characteristics of the variants are known and that the specification teaches that the polypeptides of the invention "specifically bind to anti-*Ehrlichia* antibodies".

The claims are drawn to compositions of matter and articles of manufacture comprising an isolated polypeptide consisting essentially of SEQ ID NO:2 or a phenotypically silent acid substitution variant thereof that specifically bind to an anti-*Ehrlichia* antibody. The Examiner is interpreting the compositions of matter and articles

Art Unit: 1645

of manufacture to comprise an isolated polypeptide that bind anti-*Ehrlichia* antibody.

The claims read on isolated proteins and are not limited to the amino acid sequences (SEQ ID NOs: 1-7) shown in Table 1 (page 10 of Brief on Appeal). It is the Examiner's position that there is nothing on the record to show that the specification provides adequate written description for the full scope of the claims and therefore does not meet the written description requirement as set forth in 35 U.S.C. 112, first paragraph. The specification proposes to discover other members of the genus by using a sequence comparison algorithm (pages 6-7). The specification states "that naturally occurring variants and non-naturally occurring variants are include in the invention and may be produced by mutagenesis techniques or by direct synthesis" and the specification states that "variants in which amino acids of polypeptides of the invention are substituted, deleted, added in any combination are contemplated by the invention" (page 7). The specification does not provide adequate written description for the full scope of the claimed invention. Appellant has provided no structural description accompanying the variant language (i.e. "substitution variants") recited in the claims. To address Appellant's assertions regarding, for example, substitutions at position one of SEQ ID NO:2, it should be noted that K or N, correspond to amino acids lysine and asparagine, respectively. It should also be noted that lysine is a basic amino acid and asparagine is a neutral-polar amino acid. Therefore, other basic amino acids such as arginine or histidine could be substituted for lysine at position one in the amino acid sequence as set forth in SEQ ID NO:2 and other neutral-polar amino acids such as serine, threonine, tyrosine, tryptophan, glutamine or cysteine could be substituted for asparagine at

Art Unit: 1645

position one in the amino acid sequence as set forth in SEQ ID NO:2 to produce amino acid substitution variants. Moreover, any of the known 20 amino acids could be substituted in position one or any other position along the amino acid sequence as set forth in SEQ ID NO:2 to produce substitution variants which would have to be tested to determine if the variant retains the recited function of binding anti-*Ehrlichia* antibodies. Undue experimentation would be required to select amino acid substitution variants that retained the recited function due to variable number of modifications that can be made within the amino acid sequence as set forth in SEQ ID NO:2. While use of BLAST and other sequence comparison tools are known, it is not routine in the art to screen for multiple substitutions or multiple modifications of other types and the positions within the polypeptide's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity are limited in any protein and the result of such modifications is unpredictable based on the instant disclosure. The claims broadly encompass sequences from other species, mutated sequences, splice variants, sequences that have a recited degree of identity (similarity, homology), and so forth. One skilled in the art would conclude that Appellant was not in possession of the claimed genus polypeptides by the information disclosed in the specification without undue experimentation. The general knowledge of the art concerning species does not provide any indication of how the structure of a limited number of other species is representative of unknown species. Appellant was not in possession of the claimed genus of polypeptides at the time of filing.

*Response to Arguments Traversing the Rejection of claims 1-13 under 35*

*U.S.C.112, first paragraph (enablement).*

Appellant urges that a structural description of the claimed variants is provided by the specification. Appellant urges that variants are amino acid substitution variants that have at least 85 % identity to SEQ ID NO:2 and specifically bind an anti-*Ehrlichia* antibody. Appellant urges that the partial structure of the claimed variants are known, i.e. sequences having at least 85 % identity to SEQ ID NO:2 and therefore the variants have about 17 amino acids in common with the 20 amino acid long SEQ ID NO:2 and specifically bind an anti-*Ehrlichia* antibody. Appellant asserts that Table 1 demonstrates that positions 3, 8, and 13 of SEQ ID NO:2 are highly conserved across the seven sequences and positions 1, 4, 5, 6, 7, 9, 10, 11, 12 and 15 are partially conserved across the 7 sequences that is only 2 different amino acids appear in these positions. Appellant asserts that only K or N appear as amino acids in position one across the seven sequences and one of skill in the art would recognize that variants should likely retain the amino acids at positions 3, 8 and 13 and that one of two amino acids should likely be present at positions 1, 4, 5, 6, 7, 9, 10, 11, 12 and 15. Appellant urges that one of skill in the art would recognize that position 2, 14 and 16-20 could tolerate a greater range of amino acid substitutions and therefore the specification provides guidance for the claimed variants. Appellant refers to Table 1 and urges that the specification provides structural guidance as to which amino acids can be changed and the variant polypeptides retain their biological function. Appellant urges that the standard for enablement is whether one reasonable skilled in the art could make and use the

invention for the disclosures in the patent coupled with information known in the art without undue experimentation. Appellant urges that the claims are enabled by the instant specification.

As stated above, The Examiner is interpreting the compositions of matter and articles of manufacture to comprise an isolated polypeptide that bind anti-*Ehrlichia* antibody. The claims read on isolated proteins and are not limited to the amino acid sequences (SEQ ID NOs: 1-7) shown in Table 1 (page 10 of Brief on Appeal). It is the Examiner's position that Appellant has not shown enablement for variants of SEQ ID NO:2. The specification proposes to discover other members of the genus by using a sequence comparison algorithm (pages 6-7). The specification also states "that naturally occurring variants and non-naturally occurring variants are include in the invention and may be produced by mutagenesis techniques or by direct synthesis" (page 7). The specification fails to provide guidance as to which amino acids can be changed and the polypeptides still retain their claimed biological function. In the present state of the art, the structure of a limited number of species does not provide guidance to the structure of others and is insufficient to support the claimed invention. To address Appellant's comment regarding the requirements as set forth under 35 U.S.C. 112, first paragraph, it should be noted that the 35 U.S.C. 112 first paragraph requires that Appellant teach how to "make and use" the claimed invention not how to "find" variants of SEQ ID NO:2 that specifically bind to an anti-*Ehrlichia* antibody". A structural description is required. To address Appellant's assertions regarding, for example, substitution of amino acids at position one of SEQ ID NO:2, it should be noted



Art Unit: 1645

that K or N, correspond to amino acids lysine and asparagine, respectively. It should also be noted that lysine is a basic amino acid and asparagine is a neutral-polar amino acid. Therefore, other basic amino acids such as arginine or histidine could be substituted for lysine at position one in the amino acid sequence as set forth in SEQ ID NO:2 and other neutral-polar amino acids such as serine, threonine, tyrosine, tryptophan, glutamine or cysteine could be substituted for asparagine at position one in the amino acid sequence as set forth in SEQ ID NO:2 to produce amino acid substitution variants. Moreover, any of the 20 known amino acids could be substituted in position one or any other position along the amino acid sequence as set forth in SEQ ID NO:2 to produce substitution variants which would have to be tested to determine if the variant retains the recited function of binding anti-*Ehrlichia* antibodies. Undue experimentation would be required to select amino acid substitution variants that retain the recited function due to variable number of modifications that can be made within the amino acid sequence as set forth in SEQ ID NO:2. While use of BLAST and other sequence comparison tools are known, it is not routine in the art to screen for multiple substitutions or multiple modifications of other types and the positions within the polypeptide's sequence where amino acid modifications can be made with a reasonable expectation of success in obtaining similar activity are limited in any protein and the result of such modifications is unpredictable based on the instant disclosure. The claims broadly encompass sequences from other species, mutated sequences, splice variants, sequences that have a recited degree of identity (similarity, homology), and so forth. The general knowledge of the art concerning species does not provide any

Art Unit: 1645

indication of how the structure of a limited number of other species is representative of unknown species. One skilled in the art would require guidance in order to make and use the claimed composition of matter or article of manufacture comprising amino acid substitution variants of SEQ ID NO:2 commensurate with the claims. Without such guidance the experimentation to arrive at the claimed invention would be undue.

*Response to Arguments Traversing the Rejection of claims 1-13 under U.S.C.102(a) (Rikihisa et al.).*

Appellant urges that the transitional phrase "consisting essentially of" limits the scope of a claim to the specified materials or steps that do not materially affect the basic and novel characteristics of the claimed invention". Appellant urges that the claims recite an *E. canis* polypeptide portions or fragments. Appellant urges that the claimed polypeptides can be used to detect the presence of anti-*Ehrlichia* antibodies and the fragments can also be used as reagents in assays that provide greater sensitivity than the reagents taught in Rikihisa. Appellant urges the proteins of the prior art (full-length proteins) would result in assays that are less sensitive than those disclosed in the instant specification. Appellant refers to the declaration filed under 37 C.F.R. 1.132 of Dr. Chandrashekar. Appellant urges that the addition of amino acids to the claimed isolated polypeptides so they encompass the whole proteins of Rikihisa would materially affect the basic and novel characteristics of the polypeptides.

The Examiner is interpreting the claims as compositions of matter and articles of manufacture that comprise an isolated polypeptide that bind anti-*Ehrlichia* antibody.

Art Unit: 1645

The Examiner is also viewing the compositions of matter and articles of manufacture to read on a solid support such as a wells in a microtiter plate, magnetic beads, columns, membranes and the like (instant specification pages 12-13) and not a reagent inasmuch as the claims recite compositions of matter and articles of manufacture containing the polypeptides. It should be noted that the claims recite the term "comprising" which is open claim language and the claims also recite the transitional phrase "consisting essentially of" which only refers to the isolated polypeptide set forth in SEQ ID NO:2. Therefore, the claims read on whole proteins. While claim 6 specifies *E. canis* or *E. chaffeensis*, it is only within the context of identifying an infection. The claims do not require that the polypeptides are derived from any particular *Ehrlichia* species. It should be further noted that the protein of the prior art is used to detect *Ehrlichia* antibodies. Therefore, the addition of amino acid sequences to SEQ ID NO:2 (i.e. a sequence comprising SEQ ID NO:2 as taught by the prior art) do not materially affect the basic and novel characteristic of the invention. It is the Examiner's position that Rikihisa et al anticipate the claimed invention because Rikihisa et al teach compositions of matter and articles of manufacture that comprise the isolated polypeptide as set forth in SEQ ID NO:2 (see Figure 19B for the sequence and page 11 for the compositions of matter and articles of manufacture as taught by the prior art). To address Appellant's comments regarding the Declaration of Dr. Chandrashekar, which is directed to issues regarding sensitivity and specificity, it should be remembered that there are no limitations in the claims requiring that the devices require any particular level of sensitivity. It is noted that the features upon which Appellant relies (i.e., sensitivity) are not recited in the rejected

Art Unit: 1645

claim(s). Although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. See *In re Van Geuns*, 988 F.2d 1181, 26 USPQ2d 1057 (Fed. Cir. 1993). The Declaration of Dr. Chandrashekar does not provide a comparison of the protein of the prior art and the claimed polypeptides. Therefore, the declaration of Dr. Chandrashekar is not sufficient to overcome the instant rejection.

*Response to Arguments Traversing the Rejection of claims 1-9 under U.S.C. 112, second paragraph.*

Appellant urges that one of skill in the art would know the meaning of phenotypically silent amino acid substitution variants given in the specification. Applicant urges that the specification pages 7-9 which refers to Bowie et al, *Science* 247:1306-1310 (1990) provides guidance concerning how to make phenotypically silent amino acid substitutions.

It is the Examiner's position that metes and bounds of "phenotypically silent amino acid substitutions" cannot be ascertained by what is disclosed in the instant specification. The specification and Bowie et al merely teach that amino acid modifications can be made. It should be noted that Bowie et al discloses that problems exist with the prediction structure and function from a sequence (page 1).

Art Unit: 1645

Therefore, it is not clear as to what constitutes a "phenotypically silent amino acid substitution variant".

***Examiner's Answer Conclusion***

For the above reasons, it is believed Examiner should be affirmed.


Respectfully submitted,



Vanessa L. Ford  
January 6, 2005



Lynette F. Smith  
Conferee



James O. Wilson  
Conferee

MCDONNELL BOEHNEN HULBERT & BERGHOFF LLP  
300 S. WACKER DRIVE  
32ND FLOOR  
CHICAGO, IL 60606